Strategies in the design of nanoparticles for therapeutic applications

Nature Reviews Drug Discovery

Volumn 9, Issue 8, 2010, Pages 615-627

  Petros, Robby A ^a   Desimone, Joseph M ^b,c  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c North Carolina State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ASPARAGINASE MACROGOL; CARMUSTINE; CREMOPHOR; CYCLOSPORIN A; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GLATIRAMER; GOSERELIN; LIPOSOME; MACROGOL; MESCALINE; MONOCLONAL ANTIBODY J591; MORPHINE SULFATE; NANOMATERIAL; NANOPARTICLE; ONCOSPAR; PACLITAXEL; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POVIDONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOCYTIC LEUKEMIA; BREAST CANCER; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG TARGETING; HEPATITIS C; HUMAN; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; MULTIPLE MYELOMA; MYCOSIS; NANOENCAPSULATION; NANOENGINEERING; NEUTROPENIA; OVARY CANCER; PARTICLE SIZE; POSTOPERATIVE ANALGESIA; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES;

EID: 77955175216     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2591     Document Type: Review

References (173)

1. Davis, M. E., Chen, Z. & Shin, D. M. Nanoparticletherapeutics: an emerging treatment modality forcancer. Nature Rev. Drug Discov. 7, 771-782 (2008).
2. Zhang, L. et al. Nanoparticles in medicine: therapeuticapplications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008).
3. Park, J. et al. PEGylated PLGA nanoparticles for theimproved delivery of doxorubicin. Nanomedicine 5,410-418 (2009).
4. Wang, X. et al. HFT-T, a targeting nanoparticle,enhances specific delivery of paclitaxel to folatereceptor-positive tumors. ACS Nano 3, 3165-3174(2009).
5. Torchilin, V. P. Recent advances with liposomes aspharmaceutical carriers. Nature Rev. Drug Discov. 4, 145-160 (2005).
6. Berry, G. et al. The use of cardiac biopsy todemonstrate reduced cardiotoxicity in AIDS Kaposi'ssarcoma patients treated with pegylated liposomaldoxorubicin. Ann. Oncol. 9, 711-716 (1998).
7. Ewer, M. S. et al. Cardiac safety of liposomalanthracyclines. Semin. Oncol. 31, 161-181 (2004).
8. Sharma, G., Anabousi, S., Ehrhardt, C. & Kumar, M. Liposomes as targeted drug delivery systems in thetreatment of breast cancer. J. Drug Target. 14,301-310 (2006).
9. Duncan, R. Polymer conjugates as anticancernanomedicines. Nature Rev. Cancer 6, 688-701(2006).
10. Lammers, T. & Ulbrich, K. HPMA copolymers:30 years of advances. Adv. Drug Deliv. Rev. 62,119-121 (2010).
11. Kopecek, J. & Kopeckova, P. HPMA copolymers:origins, early developments, present, and future. Adv. Drug Deliv. Rev. 62, 122-149 (2010).
12. Fukumura, D. & Jain, R. K. Imaging angiogenesis andthe microenvironment. APMIS 116, 695-715 (2008).
13. Fukumura, D. & Jain, R. K. Tumor microvasculatureand microenvironment: targets for anti-angiogenesisand normalization. Microvasc. Res. 74, 72-84(2007).
14. Jain, R. K. Transport of molecules across tumorvasculature. Cancer Metastasis Rev. 6, 559-593(1987).
15. Owens III, D. E. & Peppas, N. A. Opsonization,biodistribution, and pharmacokinetics of polymericnanoparticles. Int. J. Pharm. 307, 93-102 (2006).
16. Champion, J. A., Katare, Y. K. & Mitragotri, S. Particleshape: a new design parameter for micro-andnanoscale drug delivery carriers. J. Control. Release121, 3-9 (2007).
17. Vinogradov, S. V., Bronich, T. K. & Kabanov, A. V. Nanosized cationic hydrogels for drug delivery:preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 54, 135-147 (2002).
18. Wong, J. et al. Suspensions for intravenous (IV)injection: a review of development, preclinical andclinical aspects. Adv. Drug Deliv. Rev. 60, 939-954(2008).
19. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution ofpolymeric nanoparticles. Mol. Pharm. 5, 505-515(2008).
20. Choi, H. S. et al. Renal clearance of quantum dots. Nature Biotech. 25, 1165-1170 (2007).
21. Ilium, L. et al. Blood clearance and organ depositionof intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 12, 135-146 (1982).
22. Moghimi, S. M., Hedeman, H., Muir, I. S., Illum, L. & Davis, S. S. An investigation of the filtration capacityand the fate of large filtered sterically-stabilizedmicrospheres in rat spleen. Biochim. Biophys. Acta1157, 233-240 (1993).
23. Porter, C. J., Moghimi, S. M., Illum, L. & Davis, S. S. The polyoxyethylene/polyoxypropylene blockcopolymer poloxamer-407 selectively redirectsintravenously injected microspheres to sinusoidalendothelial-cells of rabbit bone-marrow. FEBS Lett. 305, 62-66 (1992).
24. Mitragotri, S. & Lahann, J. Physical approaches tobiomaterial design. Nature Mater. 8, 15-23 (2009).
25. Barua, S. & Rege, K. Cancer-cell-phenotype-dependentdifferential intracellular trafficking of unconjugatedquantum dots. Small 5, 370-376 (2009).
26. Moghimi, S. M., Hunter, A. C. & Murray, J. C. Longcirculatingand target-specific nanoparticles: theory topractice. Pharmacol. Rev. 53, 283-318 (2001).
27. Frank, M. M. & Fries, L. F. The role of complement ininflammation and phagocytosis. Immunol. Today 12,322-326 (1991).
28. Leu, D., Manthey, B., Kreuter, J., Speiser, P. & Deluca, P. P. Distribution and elimination of coatedpolymethyl [2-C-14]methacrylate nanoparticlesafter intravenous injection in rats. J. Pharm. Sci. 73, 1433-1437 (1984).
29. Goppert, T. M. & Muller, R. H. Polysorbate-stabilizedsolid lipid nanoparticles as colloidal carriersfor intravenous targeting of drugs to the brain:comparison of plasma protein adsorption patterns. J. Drug Target. 13, 179-187 (2005).
30. Moghimi, S. M. & Patel, H. M. Serum-mediatedrecognition of liposomes by phagocytic cells of thereticuloendothelial system\the concept of tissuespecificity. Adv. Drug Deliv. Rev. 32, 45-60 (1998).
31. Dobrovolskaia, M. A. & Mcneil, S. E. Immunologicalproperties of engineered nanomaterials. NatureNanotech. 2, 469-478 (2007). Excellent perspective regarding formal guidelinesfor the testing of nanomaterials.
32. Serda, R. E. et al. Mitotic trafficking of siliconmicroparticles. Nanoscale 1, 250-259 (2009).
33. Moghimi, S. M., Hamad, I., Andresen, T. L.,Jorgensen, K. & Szebeni, J. Methylation of thephosphate oxygen moiety of phospholipid- methoxy(polyethylene glycol) conjugate preventsPEGylated liposome-mediated complement activationand anaphylatoxin production. FASEB J. 20,2591-2593 (2006).
34. Hamad, I. et al. Complement activation by PEGylatedsingle-walled carbon nanotubes is independent of C1qand alternative pathway turnover. Mol. Immunol. 45,3797-3803 (2008).
35. Torchilin, V. P. & Trubetskoy, V. S. Which polymers canmake nanoparticulate drug carriers long-circulating. Adv. Drug Deliv. Rev. 16, 141-155 (1995).
36. Adams, M. L., Lavasanifar, A. & Kwon, G. S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 92, 1343-1355 (2003).
37. Otsuka, H., Nagasaki, Y. & Kataoka, K. PEGylatednanoparticles for biological and pharmaceuticalapplications. Adv. Drug Deliv. Rev. 55, 403-419(2003).
38. Howard, M. D., Jay, M., Dziublal, T. D. & Lu, X. L. PEG ylation of nanocarrier drug delivery systems: stateof the art. J. Biomed. Nanotechnol. 4, 133-148(2008).
39. Yokoe, J. et al. Albumin-conjugated PEG liposomeenhances tumor distribution of liposomal doxorubicinin rats. Int. J. Pharm. 353, 28-34 (2008).
40. Furumoto, K. et al. Effect of coupling of albuminonto surface of PEG liposome on its in vivo disposition. Int. J. Pharm. 329, 110-116 (2007).
41. Ogawara, K. et al. Pre-coating with serum albuminreduces receptor-mediated hepatic disposition ofpolystyrene nanosphere: implications for rationaldesign of nanoparticles. J. Control. Release 100,451-455 (2004).
42. Conner, S. D. & Schmid, S. L. Regulated portals ofentry into the cell. Nature 422, 37-44 (2003).
43. Rejman, J., Oberle, V., Zuhorn, I. S. & Hoekstra, D. Size-dependent internalization of particles via thepathways of clathrin-and caveolae-mediatedendocytosis. Biochem. J. 377, 159-169 (2004).
44. Hillaireau, H. & Couvreur, P., Nanocarriers' entry intothe cell: relevance to drug delivery. Cell. Mol. Life Sci. 66, 2873-2896 (2009).
45. Decuzzi, P., Pasqualini, R., Arap, W. & Ferrari, M. Intravascular delivery of particulate systems: doesgeometry really matter? Pharm. Res. 26, 235-243(2009).
46. Champion, J. A. & Mitragotri, S. Shape inducedinhibition of phagocytosis of polymer particles. Pharm. Res. 26, 244-249 (2009).
47. Muro, S. et al. Control of endothelial targeting andintracellular delivery of therapeutic enzymes bymodulating the size and shape of ICAM-1-targetedcarriers. Mol. Ther. 16, 1450-1458 (2008).
48. Geng, Y., et al. Shape effects of filaments versusspherical particles in flow and drug delivery. NatureNanotech. 2, 249-255 (2007).
49. Gratton, S. E., Napier, M. E., Ropp, P. A., Tian, S. M. & DeSimone, J. M. Microfabricated particles forengineered drug therapies: elucidation into themechanisms of cellular internalization of PRINTparticles. Pharm. Res. 25, 2845-2852 (2008).
50. Gratton, S. E. et al. The effect of particle design oncellular internalization pathways. Proc. Natl Acad. Sci. USA 105, 11613-11618 (2008).
51. Champion, J. A. & Mitragotri, S. Role of targetgeometry in phagocytosis. Proc. Natl Acad. Sci. USA103, 4930-4934 (2006).
52. Doshi, N. & Mitragotri, S. Designer biomaterials fornanomedicine. Adv. Funct. Mater. 19, 3843-3854(2009).
53. Lee, S. Y., Ferrari, M. & Decuzzi, P. Shapingnano-/micro-particles for enhanced vascularinteraction in laminar flows. Nanotechnology 20,495101-495111 (2009).
54. Decuzzi, P. et al. Size and shape effects in thebiodistribution of intravascularly injected particles. J. Control. Release 141, 320-327 (2010).
55. Drummond, D. C., Meyer, O., Hong, K. L.,Kirpotin, D. B. & Papahadjopoulos, D. Optimizingliposomes for delivery of chemotherapeutic agentsto solid tumors. Pharmacol. Rev. 51, 691-743(1999).
56. Thevenot, P., Hu, W. J. & Tang, L. P. Surface chemistryinfluences implant biocompatibility. Curr. Top. Med. Chem. 8, 270-280 (2008).
57. Wang, Y. X., Robertson, J. L., Spillman, W. B. & Claus, R. O. Effects of the chemical structure and thesurface properties of polymeric biomaterials on theirbiocompatibility. Pharm. Res. 21, 1362-1373 (2004).
58. Braun, K., Pipkorn, R. & Waldeck, W. Developmentand characterization of drug delivery systems fortargeting mammalian cells and tissues: a review. Curr. Med. Chem. 12, 1841-1858 (2005).
59. Byrne, J. D., Betancourt, T. & Brannon-Peppas, L. Active targeting schemes for nanoparticle systemsin cancer therapeutics. Adv. Drug Deliv. Rev. 60,1615-1626 (2008).
60. Maeda, H., Greish, K. & Fang, J. The EPR effect andpolymeric drugs: a paradigm shift for cancerchemotherapy in the 21st century. Adv. Polym. Sci. 193, 103-121 (2006).
61. Matsumura, Y. & Maeda, H. A new concept formacromolecular therapeutics in cancer-chemotherapy\mechanism of tumoritropic accumulation ofproteins and the antitumor agent Smancs. Cancer Res. 46, 6387-6392 (1986).
62. Salazar, M. D. & Ratnam, M. The folate receptor:what does it promise in tissue-targeted therapeutics?Cancer Metastasis Rev. 26, 141-152 (2007).
63. Low, P. S., Henne, W. A. & Doorneweerd, D. D. Discovery and development of folic-acid-basedreceptor targeting for imaging and therapy of cancerand inflammatory diseases. Acc. Chem. Res. 41,120-129 (2008).
64. Gabizon, A., Shmeeda, H., Horowitz, A. T. &Zalipsky, S. Tumor cell targeting of liposome-entrappeddrugs with phospholipid-anchored folic acid-PEGconjugates. Adv. Drug Deliv. Rev. 56, 1177-1192(2004).
65. Daniels, T. R., Delgado, T., Rodriguez, J. A.,Helguera, G. & Penichet, M. L. The transferrinreceptor part I: biology and targeting with cytotoxicantibodies for the treatment of cancer. Clin. Immunol. 121, 144-158 (2006).
66. Daniels, T. R., Delgado, T., Helguera, G. & Penichet, M. L. The transferrin receptor part II:targeted delivery of therapeutic agents into cancercells. Clin. Immunol. 121, 159-176 (2006).
67. Choi, C. H., Alabi, C. A., Webster, P. & Davis, M. E. Mechanism of active targeting in solid tumors withtransferrin-containing gold nanoparticles. Proc. NatlAcad. Sci. USA. 107, 1235-1240 (2010).
68. Sung, J. C., Pulliam, B. L. & Edwards, D. A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25, 563-570 (2007).
69. Roger, E., Lagarce, F., Garcion, E. & Benoit, J. P. Biopharmaceutical parameters to consider in orderto alter the fate of nanocarriers after oral delivery. Nanomedicine 5, 287-306 (2010).
70. Abra, R. M., Bosworth, M. E. & Hunt, C. A. Liposome disposition in vivo: effects of pre-dosing withlipsomes. Res. Commun. Chem. Pathol. Pharmacol. 29, 349-360 (1980).
71. Souhami, R. L., Patel, H. M. & Ryman, B. E. The effectof reticuloendothelial blockade on the blood clearanceand tissue distribution of liposomes. Biochim. Biophys. Acta 674, 354-371 (1981).
72. Moghimi, S. M. & Davis, S. S. Innovations in avoidingparticle clearance from blood by Kupffer cells: causefor reflection. Crit. Rev. Ther. Drug Carrier Syst. 11,31-59 (1994).
73. Simberg, D. et al. Biomimetic amplification ofnanoparticle homing to tumors. Proc. Natl Acad. Sci. USA 104, 932-936 (2007).
74. Passirani, C., Barratt, G., Devissaguet, J. P. & Labarre, D. Long-circulating nanoparticles bearingheparin or dextran covalently bound to poly(methylmethacrylate). Pharm. Res. 15, 1046-1050 (1998).
75. Socha, M. et al. Increase in the vascular residencetime of propranolol-loaded nanoparticles coated withheparin. J. Nanosci. Nanotechnol. 8, 2369-2376(2008).
76. Oldenborg, P. A., Gresham, H. D., Chen, Y. M., Izui, S. & Lindberg, F. P. Lethal autoimmune hemolytic anemiain CD47-deficient nonobese diabetic (NOD) mice. Blood 99, 3500-3504 (2002).
77. Shiratori, I. et al. Down-regulation of basophil functionby human CD200 and human herpesvirus-8 CD200. J. Immunol. 175, 4441-4449 (2005).
78. Bareford, L. M. & Swaan, P. W. Endocytic mechanismsfor targeted drug delivery. Adv. Drug Deliv. Rev. 59,748-758 (2007).
79. Torchilin, V. P. Cell penetrating peptide-modifiedpharmaceutical nanocarriers for intracellular drug andgene delivery. Biopolymers 90, 604-610 (2008).
80. Davis, M. E. et al. Evidence of RNAi in humans fromsystemically administered siRNA via targetednanoparticles. Nature 464, 1067-1070 (2010).
81. Davis, M. E. The first targeted delivery of siRNAin humans via a self-assembling, cyclodextrinpolymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668 (2009).
82. Napier, M. E. & DeSimone, J. M. Nanoparticle drugdelivery platform. Polymer Rev. 47, 321-327 (2007).
83. Gratton, S. E. et al. The pursuit of a scalablenanofabrication platform for use in material and lifescience applications. Acc. Chem. Res. 41, 1685-1695(2008).
84. Euliss, L. E., DuPont, J. A., Gratton, S. & DeSimone, J. Imparting size, shape, and composition control ofmaterials for nanomedicine. Chem. Soc. Rev. 35,1095-1104 (2006).
85. Rolland, J. et al. Direct fabrication and harvestingof monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127, 10096-10100 (2005).
86. Oupicky, D., Konak, C., Ulbrich, K., Wolfert, M. A. & Seymour, L. W. DNA delivery systems based oncomplexes of DNA with synthetic polycations and theircopolymers. J. Control. Release 65, 149-171 (2000).
87. Gary, D. J., Puri, N. & Won, Y. Y. Polymer-based siRNAdelivery: perspectives on the fundamental andphenomenological distinctions from polymer-basedDNA delivery. J. Control. Release 121, 64-73 (2007).
88. Saito, G., Swanson, J. A. & Lee, K. D. Drug deliverystrategy utilizing conjugation via reversible disulfidelinkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55, 199-215 (2003).
89. Niculescu-Duvaz, I. Technology evaluation:gemtuzumab ozogamicin, Celltech Group. Curr. Opin. Mol. Ther. 2, 691-696 (2000).
90. Petros, R. A., Ropp, P. A. & DeSimone, J. M. Reductively labile PRINT particles for the delivery ofdoxorubicin to HeLa cells. J. Am. Chem. Soc. 130,5008-5009 (2008).
91. Oh, J. K. et al. Biodegradable nanogels prepared byatom transfer radical polymerization as potential drugdelivery carriers: synthesis, biodegradation, in vitrorelease, and bioconjugation. J. Am. Chem. Soc. 129,5939-5945 (2007).
92. Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D. & Zalipsky, S. Liposomes with detachable polymercoating: destabilization and fusion ofdioleoylphosphatidylethanolamine vesicles triggeredby cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388, 115-118 (1996).
93. Torchilin, V. P. Targeted pharmaceutical nanocarriersfor cancer therapy and imaging. AAPS J. 9,E128-E147 (2007).
94. Oh, K. T., Yin, H. Q., Lee, E. S. & Bae, Y. H. Polymericnanovehicles for anticancer drugs with triggeringrelease mechanisms. J. Mater. Chem. 17, 3987-4001(2007).
95. Ganta, S., Devalapally, H., Shahiwala, A. & Amiji, M. A review of stimuli-responsive nanocarriers for drugand gene delivery. J. Control. Release 126, 187-204(2008).
96. Sinha, R., Kim, G. J., Nie, S. M. & Shin, D. M. Nanotechnology in cancer therapeutics: bioconjugatednanoparticles for drug delivery. Mol. Cancer Ther. 5,1909-1917 (2006).
97. Patri, A. K. et al. Synthesis and in vitro testing of J591antibody-dendrimer conjugates for targeted prostatecancer therapy. Bioconjug. Chem. 15, 1174-1181(2004).
98. Chang, S. S. et al. Prostate-specific membrane antigenis produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674-2681 (1999).
99. Milowsky, M. I. et al. Vascular targeted therapy withanti-prostate- specific membrane antigen monoclonalantibody J591 in advanced solid tumors. J. Clin. Oncol. 25, 540-547 (2007).
100. Aina, O. H. et al. From combinatorial chemistry tocancer-targeting peptides. Mol. Pharm. 4, 631-651(2007).
101. Pierschbacher, M. D. & Ruoslahti, E. Cell attachmentactivity of fibronectin can be duplicated by smallsynthetic fragments of the molecule. Nature 309,30-33 (1984).
102. Stupack, D. G. & Cheresh, D. A. Integrins andangiogenesis. Curr. Top. Dev. Biol. 64, 207-238(2004).
103. Cheresh, D. A. Structure, function and biologicalproperties of integrin alpha v beta 3 on humanmelanomacells. Cancer Metastasis Rev. 10, 3-10(1991).
104. Murphy, E. A. et al. Nanoparticle-mediated drugdelivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343-9348(2008).
105. Danhier, F. et al. Targeting of tumor endotheliumby RGD-grafted PLGA-nanoparticles loaded withpaclitaxel. J. Control. Release 140, 166-173(2009).
106. Schliemann, C. et al. In vivo biotinylation of thevasculature in B-cell lymphoma identifies BST-2as a target for antibody-based therapy. Blood 115,736-744 (2010).
107. Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting ofdrugs and nanoparticles to tumors. J. Cell Biol. 188,759-768 (2010). Describes the advantages of vascular targetingof nanoparticles to tumours.
108. Jacobson, B. S., Stolz, D. B. & Schnitzer, J. E. Identification of endothelial cell-surface proteinsas targets for diagnosis and treatment of disease. Nature Med. 2, 482-484 (1996).
109. Carson-Walter, E. B. et al. Cell surface tumorendothelial markers are conserved in mice andhumans. Cancer Res. 61, 6649-6655 (2001).
110. Sugahara, K. N. et al. Tissue-penetrating delivery ofcompounds and nanoparticles into tumors. CancerCell 16, 510-520 (2009).
111. Chan, J. M. et al. Spatiotemporal controlleddelivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA 107, 2213-2218(2010).
112. Renschler, M. F., Bhatt, R. R., Dower, W. J. & Levy, R. Synthetic peptide ligands of the antigen bindingreceptor induce programmed cell death in a humanB-cell lymphoma. Proc. Natl Acad. Sci. USA 91,3623-3627 (1994).
113. Pennell, C. A. & Scott, D. W. Lymphoma models forB cell activation and tolerance. IV. Growth inhibitionby anti-Ig of CH31 and CH33 B lymphoma cells. Eur. J. Immunol. 16, 1577-1581 (1986).
114. Miller, R. A., Maloney, D. G., Warnke, R. & Levy, R. Treatment of B-cell lymphoma with monoclonal antiidiotypeantibody. N. Engl. J. Med. 306, 517-522(1982).
115. Pouton, C. W., Wagstaff, K. M., Roth, D. M.,Moseley, G. W. & Jans, D. A. Targeted delivery to thenucleus. Adv. Drug Deliv. Rev. 59, 698-717 (2007).
116. Hodoniczky, J., Sims, C. G., Best, W. M., Bentel, J. M. & Wilce, J. A. The intracellular and nuclear-targeteddelivery of an antiandrogen drug by carrier peptides. Biopolymers 90, 595-603 (2008).
117. Misra, R. & Sahoo, S. K. Intracellular trafficking ofnuclear localization signal conjugated nanoparticlesfor cancer therapy. Eur. J. Pharm. Sci. 39, 152-163(2010).
118. Vasir, J. K. & Labhasetwar, V. Biodegradablenanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59, 718-728 (2007).
119. Zhang, Z. H. et al. Biomimetic nanocarrier for directcytosolic drug delivery. Angew. Chem. Int. Ed. Engl. 48, 9171-9175 (2009).
120. Mukhopadhyay, A. & Weiner, H. Delivery of drugs andmacromolecules to mitochondria. Adv. Drug Deliv. Rev. 59, 729-738 (2007).
121. Boddapati, S. V., D'Souza, G. G., Erdogan, S.,Torchilin, V. P. & Weissig, V. Organelle-targetednanocarriers: specific delivery of liposomal ceramideto mitochondria enhances its cytotoxicity in vitroand in vivo. Nano Lett. 8, 2559-2563 (2008).
122. Yamada, Y. & Harashima, H. Mitochondrial drugdelivery systems for macromolecule and theirtherapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev. 60, 1439-1462 (2008).
123. Yousif, L. F., Stewart, K. M. & Kelley, S. O. Targeting mitochondria with organelle-specificcompounds: strategies and applications. ChemBioChem 10, 1939-1950 (2009).
124. Terlecky, S. R. & Koepke, J. I. Drug delivery toperoxisomes: employing unique traffickingmechanisms to target protein therapeutics. Adv. Drug Deliv. Rev. 59, 739-747 (2007).
125. Breunig, M., Bauer, S. & Goefferich, A. Polymersand nanoparticles: intelligent tools for intracellulartargeting? Eur. J. Pharm. Biopharm. 68, 112-128(2008).
126. Callahan, J. & Kopecek, J. Semitelechelic HPMAcopolymers functionalized with triphenylphosphoniumas drug carriers for membrane transduction andmitochondrial localization. Biomacromolecules 7,2347-2356 (2006).
127. Hoshino, A. et al. Quantum dots targeted to theassigned organelle in living cells. Microbiol. Immunol. 48, 985-994 (2004).
128. Wagstaff, K. M. & Jans, D. A. Importins and beyond:non-conventional nuclear transport mechanisms. Traffic 10, 1188-1198 (2009).
129. Pante, N. & Kann, M. Nuclear pore complex is able totransport macromolecules with diameters of similarto 39 nm. Mol. Biol. Cell 13, 425-434 (2002).
130. Chan, C. K. & Jans, D. A. Using nuclear targetingsignals to enhance non-viral gene transfer. Immunol. Cell Biol. 80, 119-130 (2002).
131. Chan, C. K., Senden, T. & Jans, D. A. Supramolecularstructure and nuclear targeting efficiency determinethe enhancement of transfection by modifiedpolylysines. Gene Ther. 7, 1690-1697 (2000).
132. Farokhzad, O. C. & Langer, R. Impact ofnanotechnology on drug delivery. ACS Nano 3,16-20 (2009).
133. Jatzkewitz, H. Incorporation of physiologically-activesubstances into a colloidal blood plasmasubstitute. I. Incorporation of mescaline peptide intopolyvinylpyrrolidone. Hoppe-Seylers Z. Physiol. Chem. 297, 149-156 (1954) (in German).
134. Jatzkewitz, H. An ein kolloidales blutplasmaersatzmittel(polyvinylpyrrolidon) gebundenespeptamin (glycyl-l-leucyl-mezcalin) als neuartigedepotform fur biologisch aktive primare amine(mezcalin). Z. Naturforsch. B 10, 27-31 (1955)(in German).
135. Bangham, A. D. & Horne, R. W. Negative stainingof phospholipids and their structural modificationby surface-active agents as observed in theelectron microscope. J. Mol. Biol. 8, 660-668(1964).
136. Bangham, A. D., Standish, M. M. & Watkins, J. C. Diffusion of univalent ions across lamellae of swollenphospholipids. J. Mol. Biol. 13, 238-252 (1965).
137. Ringsdorf, H. Structure and properties ofpharmacologically active polymers. J. Polym. Sci. Pol. Sym. 135-153 (1975).
138. Scheffel, U., Rhodes, B. A., Natarajan T. K. & Wagner, H. N. Albumin microspheres for study ofreticuloendothelial system. J. Nucl. Med. 13,498-503 (1972).
139. Gradishar, W. J. et al. Phase III trial of nanoparticlealbumin-bound paclitaxel compared withpolyethylated castor oil-based paclitaxel in womenwith breast cancer. J. Clin. Oncol. 23, 7794-7803(2005).
140. Kopf, H., Joshi, R. K., Soliva, M. & Speiser, P. Studyon micelle polymerization in the presence of lowmolecular-weight drugs. 1. Production and isolationof nanoparticles, residual monomer determination,physical-chemical data. Pharm. Ind. 38, 281-284(1976).
141. Kreuter, J. Nanoparticles\a historical perspective. Int. J. Pharm. 331, 1-10 (2007). Describes the early history in the developmentof polymer nanoparticles for drug delivery.
142. US Food and Drug Administration. Drugs. US FDAwebsite [online], http://www. accessdata. fda. gov/scripts/cder/drugsatfda/index. cfm (2010).
143. Kim, T. Y. et al. Phase I and pharmacokinetic study ofGenexol-PM, a cremophor-free, polymeric micelleformulatedpaclitaxel, in patients with advancedmalignancies. Clin. Cancer Res. 10, 3708-3716 (2004).
144. Lee, K. S. et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulationof paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108, 241-250 (2008).
145. Lim, W. T. et al. Phase I pharmacokinetic study of aweekly liposomal paclitaxel formulation (GenexolR-PM) in patients with solid tumors. Ann. Oncol. 21,382-388 (2010).
146. Brem, H. et al. Biocompatibility of a biodegradable,controlled-release polymer in the rabbit brain. Sel. Cancer Ther. 5, 55-65 (1989).
147. Brem, H. et al. Placebo-controlled trial of safetyand efficacy of intraoperative controlled deliveryby biodegradable polymers of chemotherapy forrecurrent gliomas. Lancet 345, 1008-1012 (1995).
148. National Cancer Institute. Understanding cancerseries: angiogenesis. National Cancer Institute website[online], http://www. cancer. gov/cancertopics/understandingcancer/angiogenesis/allpages (2005).
149. Neri, D. & Bicknell, R. Tumour vascular targeting. Nature Rev. Cancer 5, 436-446 (2005).
150. Desgrosellier, J. S. & Cheresh, D. A. Integrins incancer: biological implications and therapeuticopportunities. Nature Rev. Cancer 10, 9-22 (2010). Comprehensive review of the role of integrintargeting in cancer therapeutics.
151. Rolland, J. P. et al. Solvent-resistant photocurable"liquid teflon" for microfluidic device fabrication. J. Am. Chem. Soc. 126, 2322-2323 (2004).
152. Kelly, J. Y. & DeSimone, J. M. Shape-specific,monodisperse nano-molding of protein particles. J. Am. Chem. Soc. 130, 5438-5439 (2008).
153. Gratton, S. E. et al. Nanofabricated particlesfor engineered drug therapies: a preliminarybiodistribution study of PRINT™ nanoparticles. J. Control. Release 121, 10-18 (2007).
154. Merkel, T. J. et al. Scalable, shape-specific,top-down fabrication methods for the synthesisof engineered colloidal particles. Langmuir11 Dec 2009 (doi:10. 1021/la903890h).
155. Meng, F., Hennink, W. E. & Zhong, Z. Reductionsensitivepolymers and bioconjugates for biomedicalapplications. Biomaterials 30, 2180-2198 (2009).
156. Duncan, R. Designing polymer conjugates aslysosomotropic nanomedicines. Biochem. Soc. Trans. 35, 56-60 (2007).
157. Folkman, J. & Long, D. M. The use of silicone rubberas a carrier for prolonged drug therapy. J. Surg. Res. 4, 139-142 (1964).
158. Breslow, D. S. Biologically active synthetic polymers. Pure Appl. Chem. 46, 103-113 (1976).
159. Regelson, W. Advances in intraperitoneal(intracavitary) administration of synthetic polymersfor immunotherapy and chemotherapy. J. Bioact. Compat. Polym. 1, 84-107 (1986).
160. Gregoriadis, G. Drug entrapment in liposomes. FEBS Lett. 36, 292-296 (1973).
161. Kramer, P. A. Albumin microspheres as vehicles forachieving specificity in drug delivery. J. Pharm. Sci. 63, 1646-1647 (1974).
162. Gurny, R., Peppas, N. A., Harrington, D. D. &Banker, G. S. Development of biodegradable andinjectable lattices for controlled release of potentdrugs. Drug Dev. Ind. Pharm. 7, 1-25 (1981).
163. Klibanov, A. L., Maruyama, K., Torchilin, V. P. &Huang, L. Amphipathic polyethyleneglycols effectivelyprolong the circulation time of liposomes. FEBS Lett. 268, 235-237 (1990).
164. Kattan, J. et al. Phase I clinical trial andpharmacokinetic evaluation of Doxorubicin carriedby polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10, 191-199 (1992).
165. Gref, R. et al. Biodegradable long-circulatingpolymeric nanospheres. Science 263, 1600-1603(1994).
166. Kreuter, J., Alyautdin, R. N., Kharkevich, D. A. &Ivanov, A. A. Passage of peptides through theblood-brain barrier with colloidal polymer particles(nanoparticles). Brain Res. 674, 171-174 (1995).
167. Malik, N., Evagorou, E. G. & Duncan, R. Dendrimerplatinate:a novel approach to cancer chemotherapy. Anticancer Drugs 10, 767-776 (1999).
168. Vasey, P. et al. Phase I clinical and pharmacokineticstudy of PKI [N-(2-hydroxypropyl)methacrylamidecopolymer doxorubicin]: first member of a new classof chemotherapeutic agents\drug-polymerconjugates. Clin. Cancer Res. 5, 83-94 (1999).
169. Seymour, L. W. et al. Hepatic drug targeting: phase Ievaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668-1676 (2002).
170. Danson, S. et al. Phase I dose escalation andpharmacokinetic study of pluronic polymerbounddoxorubicin (SP1049C) in patients withadvanced cancer. Br. J. Cancer 90, 2085-2091(2004).
171. Kukowska-Latallo, J. F. et al. Nanoparticle targetingof anticancer drug improves therapeutic response inanimal model of human epithelial cancer. Cancer Res. 65, 5317-5324 (2005).
172. Lee, C. C. et al. A single dose of doxorubicinfunctionalizedbow-tie dendrimer cures mice bearingC-26 colon carcinomas. Proc. Natl Acad. Sci. USA103, 16649-16654 (2006).
173. Ahmed, F. et al. Shrinkage of a rapidly growing tumorby drug-loaded polymersomes: pH-triggered releasethrough copolymer degradation. Mol. Pharm. 3,340-350 (2006).